This study is for people with heart failure (HF) and impaired kidney function. Heart failure means your heart doesn't pump blood as well as it should. The study compares two treatments: balcinrenone/dapagliflozin and dapagliflozin alone, to see which is better at preventing heart-related deaths and hospital visits. Participants will be randomly assigned to one of three groups to take pills once a day. They'll be in the study for about 22 months, which includes a screening, treatment, and follow-up period. The study takes place in 40 countries at around 700 sites.
- Length of Study: About 22 months
- Visits Needed: Multiple, as required by the study
- Eligibility: Adults with heart failure, not taking an MRA, and specific kidney function levels
How understandable was the trial content above?
Hard to understand
Easy to understand